Literature DB >> 11200373

Fusidic acid disk diffusion testing of clostridium difficile can be calibrated using single-strain regression analysis.

M Oppenheimer1, G Kronvall, I Karlsson, E Holst.   

Abstract

Single-strain regression analysis (SRA) was employed to calibrate the disk diffusion antibiotic susceptibility test for fusidic acid and Clostridium difficile. MIC determinations of 40 clinical isolates of C. difficile were performed with the E-test. The disk diffusion test was standardized according to the Swedish Reference Group for Antibiotics (SRGA). Disks used for SRA contained 1.5, 5, 15, 50 and 150 microg fusidic acid and the routine disk contained 50 microg fusidic acid. A control strain, ATCC 9689, was also tested. SRA constants A and B of the regression lines were calculated. This permitted the determination of zone breakpoints for C. difficile. When applying the pharmacological MIC S and R limits set by SRGA to the E-test results I strain of C. difficile was interpreted as resistant. Zone breakpoints corresponding to the pharmacological MIC limits and calculated using the mean SRA constants for the 40 clinical isolates lead to all strains being interpreted as susceptible. SRA calculations enable laboratories to set up calibrated disk tests with species-related and laboratory-specific interpretations.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11200373     DOI: 10.1080/003655400459540

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  2 in total

1.  Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital.

Authors:  Olle Aspevall; Annika Lundberg; Lars G Burman; Thomas Akerlund; Bo Svenungsson
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

2.  Fluconazole and voriconazole multidisk testing of Candida species for disk test calibration and MIC estimation.

Authors:  G Kronvall; I Karlsson
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.